FIELD: biotechnology.
SUBSTANCE: what is presented is an antibody or its antigen-binding fragment specifically binding human CEACAM6 and Macaca fascicularis. According to the invention, the antibodies do not react in large extent with closely related human CEACAM1, human CEACAM3 and human CEACAM5. Invention also relates to nucleic acids coding said antibody or its fragment, containing vectors and cells thereof, to methods for producing antibodies, pharmaceutical compositions.
EFFECT: antibodies can be used for treating cancer and other disorders and conditions associated with expression of CEACAM6.
20 cl, 12 dwg, 32 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
| MONOVALENT ANTIBODIES TO PROPERDIN AND FRAGMENTS OF ANTIBODIES | 2018 |
|
RU2790103C2 |
| ATRIAL NATRIURETIC PEPTIDE GRAFTED ANTIBODIES | 2019 |
|
RU2822433C2 |
| NEW ANTIBODIES AGAINST XI FACTOR AND THEIR APPLICATIONS | 2017 |
|
RU2758160C2 |
| POLYPEPTIDES THAT BIND TO THE C5 COMPONENT OR TO SERUM ALBUMIN AND THEIR FUSION PROTEINS | 2018 |
|
RU2794359C2 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT A FUSED PROTEIN IN WHICH A TUMOR-PENETRATING PEPTIDE AND AN ANTIANGIOGENIC AGENT ARE FUSED FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES | 2016 |
|
RU2727238C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
